<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer-Verlag</PublisherName>
    <PublisherLocation>New York</PublisherLocation>
  </PublisherInfo>
  <Journal>
    <JournalInfo JournalProductType="ArchiveJournal" NumberingStyle="Unnumbered">
      <JournalID>12248</JournalID>
      <JournalElectronicISSN>1550-7416</JournalElectronicISSN>
      <JournalTitle>The AAPS Journal</JournalTitle>
      <JournalAbbreviatedTitle>AAPS J</JournalAbbreviatedTitle>
      <JournalSubjectGroup>
        <JournalSubject Code="F" Type="Primary">Pharmacy</JournalSubject>
        <JournalSubject Code="F00008" Priority="1" Type="Secondary">Pharmacy</JournalSubject>
        <JournalSubject Code="B21007" Priority="2" Type="Secondary">Pharmacology/Toxicology</JournalSubject>
        <JournalSubject Code="C12002" Priority="3" Type="Secondary">Biotechnology</JournalSubject>
      </JournalSubjectGroup>
    </JournalInfo>
    <Volume>
      <VolumeInfo TocLevels="0" VolumeType="Regular">
        <VolumeIDStart>7</VolumeIDStart>
        <VolumeIDEnd>7</VolumeIDEnd>
        <VolumeIssueCount>4</VolumeIssueCount>
      </VolumeInfo>
      <Issue IssueType="Regular">
        <IssueInfo TocLevels="0">
          <IssueIDStart>1</IssueIDStart>
          <IssueIDEnd>1</IssueIDEnd>
          <IssueArticleCount>25</IssueArticleCount>
          <IssueHistory>
            <CoverDate>
              <Year>2005</Year>
              <Month>3</Month>
            </CoverDate>
          </IssueHistory>
          <IssueCopyright>
            <CopyrightHolderName>American Association of Pharmaceutical Scientists</CopyrightHolderName>
            <CopyrightYear>2005</CopyrightYear>
          </IssueCopyright>
        </IssueInfo>
        <Article ID="Art6">
          <ArticleInfo ArticleType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="Unnumbered" TocLevels="0">
            <ArticleID>71047</ArticleID>
            <ArticleDOI>10.1208/aapsj070106</ArticleDOI>
            <ArticleSequenceNumber>6</ArticleSequenceNumber>
            <ArticleTitle Language="En">Bioequivalence studies for levothyroxine</ArticleTitle>
            <ArticleFirstPage>E47</ArticleFirstPage>
            <ArticleLastPage>E53</ArticleLastPage>
            <ArticleHistory>
              <RegistrationDate>
                <Year>2008</Year>
                <Month>1</Month>
                <Day>28</Day>
              </RegistrationDate>
              <Received>
                <Year>2005</Year>
                <Month>1</Month>
                <Day>7</Day>
              </Received>
              <Accepted>
                <Year>2005</Year>
                <Month>1</Month>
                <Day>7</Day>
              </Accepted>
            </ArticleHistory>
            <ArticleCopyright>
              <CopyrightHolderName>American Association of Pharmaceutical Scientists</CopyrightHolderName>
              <CopyrightYear>2005</CopyrightYear>
            </ArticleCopyright>
            <ArticleGrants Type="Regular">
              <MetadataGrant Grant="OpenAccess"/>
              <AbstractGrant Grant="OpenAccess"/>
              <BodyPDFGrant Grant="Restricted"/>
              <BodyHTMLGrant Grant="Restricted"/>
              <BibliographyGrant Grant="Restricted"/>
              <ESMGrant Grant="Restricted"/>
            </ArticleGrants>
            <ArticleContext>
              <JournalID>12248</JournalID>
              <VolumeIDStart>7</VolumeIDStart>
              <VolumeIDEnd>7</VolumeIDEnd>
              <IssueIDStart>1</IssueIDStart>
              <IssueIDEnd>1</IssueIDEnd>
            </ArticleContext>
          </ArticleInfo>
          <ArticleHeader>
            <AuthorGroup>
              <Author AffiliationIDS="Aff1" CorrespondingAffiliationID="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Sanford</GivenName>
                  <FamilyName>Bolton</FamilyName>
                </AuthorName>
                <Contact>
                  <Phone>(520) 529-9445</Phone>
                  <Fax>(520) 529-9445</Fax>
                  <Email>bolton@acninc.net</Email>
                </Contact>
              </Author>
              <Affiliation ID="Aff1">
                <OrgDivision>Sanford Bolton</OrgDivision>
                <OrgName>University of Arizona</OrgName>
                <OrgAddress>
                  <Street>5495 North Via Velazquez</Street>
                  <Postcode>85750</Postcode>
                  <City>Tucson</City>
                  <State>AZ</State>
                </OrgAddress>
              </Affiliation>
            </AuthorGroup>
            <Abstract ID="Abs1" Language="En">
              <Heading>Abstract</Heading>
              <Para>The Food and Drug Administration (FDA) Guidance for Bioavailability and Bioequivalence Studies for Levothyroxine has been challenged by companies that manufacture brand-name products. Their contention is that the current guidance does not adequately address the endogenous background levels of the drug, and that the ratios of the PK parameters, a basis for approval of equivalence, are not assessed correctly. In particular, they conclude that products that have a potency differing by 12.5% cannot be differentiated using the present guideline and criteria for acceptance of bioequivalence. They claim that such a difference can be a public health hazard because of the perception among practitioners that levothyroxine is a narrow therapeutic index drug. This article describes the procedure recommended in the current Guidance for Levothyroxine and demonstrates that the methods recommended are adequate and will accept products that are therapeutically equivalent. To date, no generic product accepted as equivalent using FDA Guidances has been shown to result in a safety and efficacy profile different from its brand counterpart.</Para>
            </Abstract>
            <ArticleNote Type="Misc">
              <SimplePara>Published: March 30, 2005.</SimplePara>
            </ArticleNote>
          </ArticleHeader>
          <BodyRef FileRef="BodyRef/PDF/12248_2008_Article_71047.pdf" TargetType="OnlinePDF"/>
          <ArticleBackmatter>
            <Bibliography ID="Bib1">
              <Heading>References</Heading>
              <Citation ID="CR1">
                <CitationNumber>1.</CitationNumber>
                <BibUnstructured>Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry Levothyroxine Sodium Tablets—In Vivo Pharmacokinetic and Bioavailability Studies and In Vitro Dissolution Testing. Rockville, MD: February 2001.</BibUnstructured>
              </Citation>
              <Citation ID="CR2">
                <CitationNumber>2.</CitationNumber>
                <BibUnstructured>Citizen's Petition. Jones Pharma, Inc. March 28, 2003.</BibUnstructured>
              </Citation>
              <Citation ID="CR3">
                <CitationNumber>3.</CitationNumber>
                <BibUnstructured>Citizen's Petition. Abbott Laboratories. August 25, 2003.</BibUnstructured>
              </Citation>
              <Citation ID="CR4">
                <CitationNumber>4.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>V</Initials>
                    <FamilyName>Blakesley</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>W</Initials>
                    <FamilyName>Awni</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Locke</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Ludden</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>GR</Initials>
                    <FamilyName>Granneman</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>LE</Initials>
                    <FamilyName>Braverman</FamilyName>
                  </BibAuthorName>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Are bioequivalence studies of levothyroxine sodium formulations in euthyroid volunteers reliable?</ArticleTitle>
                  <JournalTitle>Thyroid</JournalTitle>
                  <VolumeID>14</VolumeID>
                  <FirstPage>191</FirstPage>
                  <LastPage>200</LastPage>
                  <Occurrence Type="PID">
                    <Handle>15072701</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1089/105072504773297867</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2cXisVWgtL4%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Blakesley V, Awni W, Locke C, Ludden T, Granneman GR, Braverman LE. Are bioequivalence studies of levothyroxine sodium formulations in euthyroid volunteers reliable?<Emphasis Type="Italic">Thyroid</Emphasis>. 2004;14:191–200.</BibUnstructured>
              </Citation>
              <Citation ID="CR5">
                <CitationNumber>5.</CitationNumber>
                <BibUnstructured>Food and Drug Administration. FDA Advisory Committee for Pharmaceutical Science.<Emphasis Type="Italic">Briefing Document From Abbott Laboratories</Emphasis>. Rockville, MD; May 12–13, 2003. Available at: http://www.fda.gov/ ohrms/dockets/ac/03/briefing/3926B1_02_A-Abbott%20.htm. Accessed March 23, 2005.</BibUnstructured>
              </Citation>
              <Citation ID="CR6">
                <CitationNumber>6.</CitationNumber>
                <BibBook>
                  <InstitutionalAuthorName>Mylan Laboratories, Inc</InstitutionalAuthorName>
                  <Year>2000</Year>
                  <BookTitle>Levothyroxine Sodium Tablets</BookTitle>
                  <PublisherName>Mylan Laboratories, Inc</PublisherName>
                  <PublisherLocation>Canonsburg, PA</PublisherLocation>
                  <FirstPage>76</FirstPage>
                  <LastPage>187</LastPage>
                </BibBook>
                <BibUnstructured>Mylan Laboratories, Inc.<Emphasis Type="Italic">Levothyroxine Sodium Tablets</Emphasis>. Canonsburg, PA: Mylan Laboratories, Inc; 2000:76–187.</BibUnstructured>
              </Citation>
              <Citation ID="CR7">
                <CitationNumber>7.</CitationNumber>
                <BibUnstructured>Food and Drug Administration. FDA Advisory Committee for Pharmaceutical Science. Record of Proceedings. March 13, 2003. Available at: http://www.fda.gov/ohrms/dockets/ac/cder03.html# Pharmaceutical Science. Accessed March 23, 2005.</BibUnstructured>
              </Citation>
              <Citation ID="CR8">
                <CitationNumber>8.</CitationNumber>
                <BibUnstructured>Citizen's Petition. Abbott Laboratories. August 25, 2003.</BibUnstructured>
              </Citation>
              <Citation ID="CR9">
                <CitationNumber>9.</CitationNumber>
                <BibUnstructured>Food and Drug Administration. FDA Response to Abbott Petition, Citizen's Petition #2003P-0126/CP1, Document PDN 1. June 29, 2004.</BibUnstructured>
              </Citation>
              <Citation ID="CR10">
                <CitationNumber>10.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Carr</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DT</Initials>
                    <FamilyName>McLeod</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Parry</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>HM</Initials>
                    <FamilyName>Thornes</FamilyName>
                  </BibAuthorName>
                  <Year>1988</Year>
                  <ArticleTitle Language="En">Fine adjustment of thyroxine replacement dosage: comparison of the thyrotrophin releasing hormone test using a sensitive thyrotrophin assay with measurement of free thyroid hormones and clinical assessment</ArticleTitle>
                  <JournalTitle>J Clin Endocrinol</JournalTitle>
                  <VolumeID>28</VolumeID>
                  <FirstPage>325</FirstPage>
                  <LastPage>333</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1111/j.1365-2265.1988.tb01219.x</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:BiaD3czmvV0%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Carr D, McLeod DT, Parry G, Thornes HM. Fine adjustment of thyroxine replacement dosage: comparison of the thyrotrophin releasing hormone test using a sensitive thyrotrophin assay with measurement of free thyroid hormones and clinical assessment.<Emphasis Type="Italic">J Clin Endocrinol</Emphasis>. 1988;28:325–333.</BibUnstructured>
              </Citation>
              <Citation ID="CR11">
                <CitationNumber>11.</CitationNumber>
                <BibUnstructured>Food and Drug Administration. Code of Federal Regulations. Title 21, Volume 5: CFR 320.33. Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfefr/CFRSearch.cfm?fr=320.24. Accessed: March 23, 2005.</BibUnstructured>
              </Citation>
              <Citation ID="CR12">
                <CitationNumber>12.</CitationNumber>
                <BibBook>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Bolton</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Bon</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <BookTitle>Pharmaceutical Statistics, Practical and Clinical Applications</BookTitle>
                  <EditionNumber>4th ed</EditionNumber>
                  <PublisherName>Marcel Dekker</PublisherName>
                  <PublisherLocation>New York, NY</PublisherLocation>
                </BibBook>
                <BibUnstructured>Bolton S, Bon C.<Emphasis Type="Italic">Pharmaceutical Statistics, Practical and Clinical Applications</Emphasis>. 4th ed. New York, NY: Marcel Dekker; 2003.</BibUnstructured>
              </Citation>
              <Citation ID="CR13">
                <CitationNumber>13.</CitationNumber>
                <BibUnstructured>Health Canada. Expert Advisory Committee on Bioavailability. Record of Proceedings. April 16, 2003. Available at http://www.hc-sc.gc.ca/hpfbdgpsa/tpd-dpt/2003-04-16_e.html. Accessed March 23, 2005.</BibUnstructured>
              </Citation>
            </Bibliography>
          </ArticleBackmatter>
        </Article>
      </Issue>
    </Volume>
  </Journal>
</Publisher>
